These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36287202)

  • 21. MITOL-mediated DRP1 ubiquitylation and degradation promotes mitochondrial hyperfusion in a CMT2A-linked MFN2 mutant.
    Das R; Kamal IM; Das S; Chakrabarti S; Chakrabarti O
    J Cell Sci; 2022 Jan; 135(2):. PubMed ID: 34870686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A late-onset and mild form of Charcot-Marie-Tooth disease type 2 caused by a novel splice-site mutation within the Mitofusin-2 gene.
    Kotruchow K; Kabzińska D; Hausmanowa-Petrusewicz I; Kochański A
    Acta Myol; 2013 Dec; 32(3):166-9. PubMed ID: 24803844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cohort study of MFN2 mutations and phenotypic spectrums in Charcot-Marie-Tooth disease 2A patients.
    Choi BO; Nakhro K; Park HJ; Hyun YS; Lee JH; Kanwal S; Jung SC; Chung KW
    Clin Genet; 2015 Jun; 87(6):594-8. PubMed ID: 24863639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.
    White MA; Lin Z; Kim E; Henstridge CM; Pena Altamira E; Hunt CK; Burchill E; Callaghan I; Loreto A; Brown-Wright H; Mead R; Simmons C; Cash D; Coleman MP; Sreedharan J
    Acta Neuropathol Commun; 2019 Oct; 7(1):166. PubMed ID: 31661035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study.
    Pipis M; Feely SME; Polke JM; Skorupinska M; Perez L; Shy RR; Laura M; Morrow JM; Moroni I; Pisciotta C; Taroni F; Vujovic D; Lloyd TE; Acsadi G; Yum SW; Lewis RA; Finkel RS; Herrmann DN; Day JW; Li J; Saporta M; Sadjadi R; Walk D; Burns J; Muntoni F; Ramchandren S; Horvath R; Johnson NE; Züchner S; Pareyson D; Scherer SS; Rossor AM; Shy ME; Reilly MM;
    Brain; 2020 Dec; 143(12):3589-3602. PubMed ID: 33415332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics.
    Larrea D; Pera M; Gonnelli A; Quintana-Cabrera R; Akman HO; Guardia-Laguarta C; Velasco KR; Area-Gomez E; Dal Bello F; De Stefani D; Horvath R; Shy ME; Schon EA; Giacomello M
    Hum Mol Genet; 2019 Jun; 28(11):1782-1800. PubMed ID: 30649465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of a Novel c.820C>T (Arg274Trp) Mutation in the Mitofusin 2 Gene on Fibroblast Metabolism and Clinical Manifestation in a Patient.
    Beręsewicz M; Boratyńska-Jasińska A; Charzewski Ł; Kawalec M; Kabzińska D; Kochański A; Krzyśko KA; Zabłocka B
    PLoS One; 2017; 12(1):e0169999. PubMed ID: 28076385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MFN2 mutations cause severe phenotypes in most patients with CMT2A.
    Feely SM; Laura M; Siskind CE; Sottile S; Davis M; Gibbons VS; Reilly MM; Shy ME
    Neurology; 2011 May; 76(20):1690-6. PubMed ID: 21508331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Torin1 restores proliferation rate in Charcot-Marie-Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation.
    Zanfardino P; Amati A; Petracca EA; Santorelli FM; Petruzzella V
    Acta Myol; 2022; 41(4):201-206. PubMed ID: 36793649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation.
    Guillet V; Gueguen N; Cartoni R; Chevrollier A; Desquiret V; Angebault C; Amati-Bonneau P; Procaccio V; Bonneau D; Martinou JC; Reynier P
    FASEB J; 2011 May; 25(5):1618-27. PubMed ID: 21285398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitophagy suppresses motor neuron necroptotic mitochondrial damage and alleviates necroptosis that converges to SARM1 in acrylamide-induced dying-back neuropathy.
    Wang S; Yang Y; Yu Z; Song M; Liu Z; Shan S; Yong H; Ni W; Qiang Y; Zhang C; Wang S; Zhao X; Song F
    J Neurochem; 2023 Aug; 166(3):588-608. PubMed ID: 37350308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondrial dynamics and inherited peripheral nerve diseases.
    Pareyson D; Saveri P; Sagnelli A; Piscosquito G
    Neurosci Lett; 2015 Jun; 596():66-77. PubMed ID: 25847151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations.
    Detmer SA; Chan DC
    J Cell Biol; 2007 Feb; 176(4):405-14. PubMed ID: 17296794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Charcot-Marie-Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease.
    Hikiami R; Yamashita H; Koita N; Jingami N; Sawamoto N; Furukawa K; Kawai H; Terashima T; Oka N; Hashiguchi A; Takashima H; Urushitani M; Takahashi R
    J Hum Genet; 2018 Jan; 63(1):89-92. PubMed ID: 29215088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot-Marie-Tooth disease Type 1A mouse model.
    Moss KR; Johnson AE; Bopp TS; Yu AT; Perry K; Chung T; Höke A
    J Peripher Nerv Syst; 2022 Mar; 27(1):58-66. PubMed ID: 35137510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features.
    Bombelli F; Stojkovic T; Dubourg O; Echaniz-Laguna A; Tardieu S; Larcher K; Amati-Bonneau P; Latour P; Vignal O; Cazeneuve C; Brice A; Leguern E
    JAMA Neurol; 2014 Aug; 71(8):1036-42. PubMed ID: 24957169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the CaMKII-Sarm1-ASK1-p38 MAP kinase pathway protects against axon degeneration caused by loss of mitochondria.
    Ding C; Wu Y; Dabas H; Hammarlund M
    Elife; 2022 Mar; 11():. PubMed ID: 35285800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early onset Charcot-Marie-Tooth neuropathy type 2A and severe developmental delay: expanding the clinical phenotype of MFN2-related neuropathy.
    Tufano M; Cappuccio G; Terrone G; Manganelli F; Pisciotta C; Geroldi A; Capponi S; Del Giudice E
    J Peripher Nerv Syst; 2015 Dec; 20(4):415-8. PubMed ID: 26307494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axonal Transport Defects in a Mitofusin 2 Loss of Function Model of Charcot-Marie-Tooth Disease in Zebrafish.
    Chapman AL; Bennett EJ; Ramesh TM; De Vos KJ; Grierson AJ
    PLoS One; 2013; 8(6):e67276. PubMed ID: 23840650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural insights of human mitofusin-2 into mitochondrial fusion and CMT2A onset.
    Li YJ; Cao YL; Feng JX; Qi Y; Meng S; Yang JF; Zhong YT; Kang S; Chen X; Lan L; Luo L; Yu B; Chen S; Chan DC; Hu J; Gao S
    Nat Commun; 2019 Oct; 10(1):4914. PubMed ID: 31664033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.